BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, today announced that it has received a deficiency letter ('Letter') from NYSE American LLC ('NYSE American' or the 'Exchange') stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ('Company Guide').

BEDMINSTER，N.J.，2023年9月22日（GLOBE NEWSWIRE）-Matinas BioPharma（NYSE American:MTNB），一家临床阶段的生物制药公司，专注于利用其脂质纳米晶体（LNC）平台技术重新定义小分子和小寡核苷酸的细胞内递送，今天宣布它已收到NYSE American LLC（'NYSE American'或'交易所'）的缺陷信（'信件'），声明该公司不符合第1003（f）节中规定的持续上市标准。（v）NYSE American Company Guide（'公司指南'）。

The Letter stated that because the Company's common stock had been trading for a low price per share for a substantial period of time, the Company was not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff determined that the Company's continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time or effecting a reverse stock split of its common stock by March 21, 2024, which could be extended under certain circumstances.

该信函指出，由于本公司普通股长期以低价股票交易，本公司不符合本公司指南第1003（f）（v）条的规定。纽约证券交易所美国工作人员确定，该公司的持续上市是基于它在合理的时间内表现出持续的价格上涨或在2024年3月21日之前实现普通股的反向股票拆分，这可以在某些情况下延长。

The Company intends to regain compliance with the NYSE American’s continued listing standards by undertaking a measure or measures that are for the best interests of the Company and its stockholders. The Letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on the NYSE American under the symbol “MTNB”.

该公司打算通过采取一项有利于公司及其股东利益的措施或措施，恢复对纽约证券交易所美国持续上市标准的遵守情况。该信函对公司普通股的上市或交易没有直接影响，普通股将继续以“MTNB”符号在纽约证券交易所进行交易。

Additionally, the Letter does not result in the immediate delisting of the Company’s stock from the NYSE American. The Company’s receipt of the Letter does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission. The Company is actively engaged in discussions w.

此外，这封信不会导致该公司股票立即从纽约证券交易所美国股票中脱牌。本公司收到信函不会影响本公司与证券交易委员会的业务，运营或报告要求。公司积极参与讨论。